Johnson & Johnson Q4 Profit Decreases

Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...
Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
Ben Johnson's goal: Tearing down Caleb Williams and building him back up
The fix is in for Caleb Williams, and it's going to be done for the Bears' second-year QB by his new head coach.
Johnson & Johnson says positioned for 5%-7% growth through 2030 and beyond
Says starting 2025 from a position of strength. Says invested ~$50B in R&D and M&A in 2024. Says continues to invest in R&D at ...
MassDevice17h
Johnson & Johnson MedTech sales grow 6.2% in 2025, driven by EP, Abiomed
Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...
Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance
Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Johnson & Johnson has secured FDA approval for expanded use of its Spravato nasal spray, now cleared as a standalone ...